UNSPSC 51272201: Aliflurane

This classification denotes an anesthetic agent with the molecular formula C4H3ClF4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q1069WKM8G, chemically known as 2-chloro-1,2,3,3-tetrafluorocyclopropyl methyl ether but generally known as aliflurane, which bears US NIH Compound Identifier 41967. European Medicines Agency schedules Aliflurane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05326MIG.

UNSPSC 51272201 Aliflurane is a Commodity code that nominally designates a specific volatile anesthetic agent, but recent state and local solicitations tagged under this code show little activity purchasing aliflurane itself. Instead, the recorded opportunities reflect broader pharmaceutical and drug-management procurement: Seminole County, Florida solicited naloxone and drug deactivation systems; the Texas Health and Human Services Commission issued a Request for Information on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) sought generic multi-source pharmaceuticals and over-the-counter products across participating state and local jurisdictions. This pattern suggests the code captures emergency medical supplies and pharmaceutical distribution services more broadly than the specific anesthetic named in the taxonomy. State and local buyers using this code include county health departments, state health agencies, cooperative purchasing consortia, and community health systems. Work solicited ranges from emergency medical countermeasures (naloxone supply chains) to large-scale pharmaceutical sourcing through established wholesale networks serving multiple state and local facilities.

Activity is concentrated in Florida and the Upper Midwest (Minnesota, Oregon), with Texas HHS exploring new contracting models for pharmacy benefit management. The Seminole County procurement (IFB 60459723LAS, response due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually on a two-year base with one-year renewal option, with quarterly deliveries to the county community health building and all shipping included in pricing. The Minnesota MMCAP RFP (S1070000015802, response due March 26, 2026) established contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, with awards effective July 1, 2026, evaluated primarily on price competitiveness (75 percent weight) and administrative compliance; vendors must certify cGMP and Drug Supply Chain Security Act compliance and maintain relationships with at least two of three specified wholesalers. The Texas RFI (HHS0017013, posted April 3, 2026) was exploratory, seeking vendor capacity for direct-to-manufacturer prescription arrangements outside traditional pharmacy benefit manager channels.